Hamtandi Magloire Natama

Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial

Mehreen S. Datoo, Hamtandi Magloire Natama, Ousmane Traoré et al. · The Lancet · 2021 · 431 citations · Full text

Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial

Mehreen S. Datoo, Alassane Dicko, Halidou Tinto et al. · The Lancet · 2024 · 296 citations · Full text

Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial

Mehreen S. Datoo, Hamtandi Magloire Natama, Duncan Bellamy et al. · The Lancet Infectious Diseases · 2022 · 268 citations

Vaccination, Clinical Malaria, Burkina Faso +8

Genomic and environmental risk factors for cardiometabolic diseases in Africa: methods used for Phase 1 of the AWI-Gen population cross-sectional study

Stuart A. Ali, Cassandra Claire Soo, Godfred Agongo et al. · Global Health Action · 2018 · 139 citations · Full text

Physical Activity, Nutritional Epidemiology, Cardiometabolic Risk +26

Community-based Malaria Screening and Treatment for Pregnant Women Receiving Standard Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine: A Multicenter (The Gambia, Burkina Faso, and Benin) Cluster-randomized Controlled Trial

Susana Scott, Umberto D’Alessandro, Lindsay Kendall et al. · Clinical Infectious Diseases · 2018 · 42 citations · Full text